Excessive Pharmaceutical Prices as an Anticompetitive Practice in TRIPS and European Competition Law
Research output: Chapter in Book/Report/Conference proceeding › Book chapter › Research › peer-review
Such a treatment of excessive prices under competition law would constitute a sound legal basis for anti-competetive enforcement such as compuslory licensing but also make other tools available to competition authorities such as fines. This could be done making use of the flexibilities entailed in this regard in the TRIPS agreement context, mainly through article 31(k) and article 40.
Shifting focus to the European Competition Law, the notion of “unfair” or excessive prices has been enshrined in article 102 TFEU regarding exploitative pricing abuses by a dominant firm, although the application and enforcement of this has been rather limited in practice. Recent case law and an evoloution of thought regarding competition law and legal-economics theories point however to a possible policy shift in this regard.
The paper hence analyses the unlocked potential entailed in competition law in treating excessive pharmaceutical prices as an anticompetitive practice where applicable and discusses the legal-economic theories underpinning this discourse.
|Title of host publication||New Developments in Competition Law and Economics|
|Editors||Klaus Mathis, Avishalom Tor|
|Number of pages||24|
|Publication date||15 Mar 2019|
|Publication status||Published - 15 Mar 2019|
|Event||7th Law and Economics Conference in Lucerne: New Developments in Competition Law and Economics - University of Lucerne, Lucerne, Switzerland|
Duration: 13 Apr 2018 → 14 Apr 2018
|Conference||7th Law and Economics Conference in Lucerne|
|Location||University of Lucerne|
|Periode||13/04/2018 → 14/04/2018|
Conference Paper for 7th Law and Economics Conference in Lucerne, Switzerland. Forthcoming at Springer Verlag in 2019 in "New Developments in Competition Law and Economics" edited by Prof. Dr. Klaus Mathis and Prof. Avishalom Tor.
- Faculty of Law - Excessive Prices, Competition Law, Intellectual Property Law, pharmaceutical policy, Competition policy, patent law, abuse of dominant position, Article 102 TFEU, Excessive pricing, Unfair prices, Unfair Pricing, EU competition law, EU Intellectual Property Law, Legal Economics, Chicago School of Economics, Ordo-liberal Manifesto